News Madrigal closes on EU approval of first MASH treatment Madrigal Pharma could be just weeks away from becoming the first drugmaker to claim EU approval for a MASH treatment.
News GSK pays $1.2bn for liver drug as it culls TIGIT programme GSK decided to abandon a TIGIT-targeted drug for cancer this week, then hatched a plan to replace it with a candidate for liver disease MASH.
R&D Navigating the complexities of drug development in hepatolog... In the realm of medical research, liver disease remains a complex and often overlooked field.
News EMA panel endorses AI for MASH clinical trials PathAI's artificial intelligence tool for diagnosing MASH has become the first to be recommended under the EMA's Qualification Opinion framework.
News Novo Nordisk will file semaglutide for MASH next year Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US
R&D The growing challenge of conducting clinical trials for meta... Liver disease is on the rise around the world, posing a significant health concern.
News New UK PM shuts down science and tech department In the midst of appointing his Cabinet, new UK Prime Minister Andy Burnham has scrapped the Department for Science, Innovation and Technology (DSIT).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
